How helpful was this article to you or your practice?
- Your Rating
-
- Overall Rating
-
( reviews )
Clinical Trial Listings: Renal Cell Carcinoma
| Product Name/Compound | Unique Protocol ID | Conditions | Brief Title | Study Phase | Status |
|---|---|---|---|---|---|
| Combination of Temsirolimus and Sunitinib | 3066K1-402 | Renal Cell Carcinoma, | A Study Combining Treatment with Temsirolimus and Sunitinib for Subjects with Advanced Renal Cell Carcinoma | Phase 1/Phase 2 | Terminated |
| Temsirolimus (CCI-779) | 3066K1-2217 | Advanced Renal Cell Carcinoma, | Study Evaluating the Efficacy & Pharmacokinetics of Temsirolimus(CCI-779) in Subjects with Advanced Renal Cell Carcinoma | Phase 2 | Active, not recruiting |
| Bevacizumab + Temsirolimus | 3066K1-3311 | Renal Cell Carcinoma, kidney cancer, renal cell carcinoma, urogenital cancer, | Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects | Phase 3 | Recruiting |
| Temsirolimus | 3066K1-404 | Renal Cell Carcinoma, renal cell carcinoma, | Temsirolimus versus Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Have Failed First-Line Sunitinib | N/A | Recruiting |
Back to Clinical Trial Listing Page
Have a question about our clinical trials? Send an email to clintrialparticipation@wyeth.com
The content on this page summarizes current scientific and medical research being conducted by Wyeth Pharmaceuticals. The intervention used in this study is investigational and is not available commercially. The safety and efficacy of this intervention has not been determined and this intervention has not been approved by FDA. No promotional claims about the products or product indications listed here should be inferred.